Oncoimmunology

Article	Citations
Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer	75
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer	71
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity	53
Ferroptosis becomes immunogenic: implications for anticancer treatments	52
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies	52
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	52
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer	49
Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment	49
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer	48
Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer	45
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells	45
YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration	45
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma	40
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	38
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity	38
Integrated analyses of m 1 A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer	36
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related	33
Tumors exploit CXCR4 hi CD62L lo aged neutrophils to facilitate metastatic spread	33
The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis	33
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer	33
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study	32
Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo	32
Association between immune-related adverse event timing and treatment outcomes	31
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients	31
Trial watch: intratumoral immunotherapy	31

Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer	30
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis	30
Tumor-intrinsic determinants of immunogenic cell death modalities	30
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells	30
Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma	29
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	29
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma	29
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine	28
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors	28
The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer	28
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry	28
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs	28
Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma	27
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer	27
Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells	27
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	27
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer	26
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness	26
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer	26
Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells	26
Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer	26
Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling	25
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy	25
PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular car	25
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer	25
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma	24
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer	24
The dark side of ferroptosis in pancreatic cancer	24
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	24
Novel deep learning-based survival prediction for oral cancer by analyzing tumor-infiltrating lymphocyte profiles through CIBERSORT	23
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis	23
Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma	23
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	23
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer	23
Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12	23
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients	22
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data	22
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma	22
Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion	21
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy	21
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers	21
T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer	21
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma	21
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity	21
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors	21
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma	21
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures	21
Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer	21
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients	21
Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An	21

Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy	21
PD-L2 based immune signature confers poor prognosis in HNSCC	20
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma	20
Cross-reactivity between cancer and microbial antigens	20
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy	20
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner	20
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer	20
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538	20
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer	20
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma	20
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers	19
PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma	19
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	19
Cldn-7 deficiency promotes experimental colitis and associated carcinogenesis by regulating intestinal epithelial integrity	19
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs	19
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer	19
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	19
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis	19
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1	19
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents	19
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma	18
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy	18
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response	18
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer	18
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells	18
Immunotherapy approaches for the treatment of diffuse midline gliomas	18
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer	18
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity	18
Immunological alternation in COVID-19 patients with cancer and its implications on mortality	18
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy	18
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	18
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma	17
TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth	17
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients	17
Alternol triggers immunogenic cell death via reactive oxygen species generation	17
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival	17
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells	17
Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients	17
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy	17
Increased frequency of TIGIT + CD73-CD8 + T cells with a TOX + TCF-1low profile in patients wit	17
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma	17
DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles	17
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	17
Double-edged effects of interferons on the regulation of cancer-immunity cycle	17
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma	16
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML	16
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	16
Trial watch: chemotherapy-induced immunogenic cell death in oncology	16
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study	16
Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas	16
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma	16
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting	16
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	16
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes	15
Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response	15
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	15
Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors	15
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	15
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	15
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding	15
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	14
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells	14
Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma	14
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation	14
Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients	14
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition	14
Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis	14
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy	14
PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer	14
T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production	14
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response	14
Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling	14
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients	14
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1	14
Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy	13
MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma	13
CD34 + progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg null	13
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis	13
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade	13
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies	13

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	13
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	13
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma	13
Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct	13
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy	13
Distinct microbial communities colonize tonsillar squamous cell carcinoma	13
Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma	13
Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing	13
Trial watch: Toll-like receptor ligands in cancer therapy	12
Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation	12
Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers	12
Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy	12
Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer	12
Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma	12
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development	12
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers	12
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma	12
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1	12
CD80 expression is upregulated by TP53 activation in human cancer epithelial cells	12
Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations	12
A novel role for an old target: CD45 for breast cancer immunotherapy	12
Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?	12
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival	12
Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma	12
B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients	11
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	11
Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma	11
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)	11
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	11
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.	11
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade	11
Prognostic value of the PrP C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype	11
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	11
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma	11
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies	11
Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy	11
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer	11
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	11
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma	11
Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress	10
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	10
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	10
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma	10
Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity	10
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	10
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	10
Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance	10
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy	10
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy	10
NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription	10
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response	10
An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis	10
Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1	10
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors	10
Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)	10
License to kill: microsatellite instability and immune contexture	10
What role for AHR activation in IL4I1-mediated immunosuppression ?	9
The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer	9
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality	9
Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients	9
Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer	9
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma	9
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	9
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	9
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	9
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial	9
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation	9
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines	9
Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer	9
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	9
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma	9
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes	9
Evasion before invasion: Pre-cancer immunosurveillance	9
Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice	9
Monoacylglycerol lipase deficiency in the tumor microenvironment slows tumor growth in non-small cell lung cancer	9
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors	9
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	9
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse	9
Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma	9
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma	9
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	9
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects	9
Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADO	9
Translocation of Helicobacter hepaticus synergizes with myeloid-derived suppressor cells and contributes to breast carcinogenesis	8
Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma	8
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	8
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	8
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism	8
Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients	8
Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers	8
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection	8
Integrating CD4 + T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model	8
Enriched circulating and tumor-resident TGF-β+regulatory B cells in patients with melanoma promote FOXP3+Tregs	8
Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1	8
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	8